Arkema (ENXTPA:AKE) just committed €10 million to expand its Global Battery Center of Excellence in France, a move that puts its advanced battery materials research and broader low carbon acrylic investments in tighter focus for investors.
Against that backdrop, Arkema's share price has eased 8.1% over the past month but still shows a 4.01% year to date share price return, while the 12.77% total shareholder return over one year contrasts with much weaker 3 and 5 year total shareholder returns. This suggests that recent momentum is rebuilding from a much lower long term base as fresh investments and management changes reset expectations around both growth prospects and execution risk.
Spot under-the-radar materials specialists riding similar battery and low carbon themes as Arkema by scanning our curated list of 620 high quality undiscovered gems .
After that €10 million battery push and a 4.01% gain so far this year, Arkema still screens at a hefty intrinsic discount. Has most of the rerating already played out, or is the bigger upside just starting?
Most Popular Narrative: 14.4% Undervalued
Against Arkema's last close of €54.45, the most followed narrative points to a fair value of €63.63, implying the current share price sits at a clear discount while still incorporating execution and macro risks.
The company's sustained emphasis on R&D and innovation (especially in differentiated materials for batteries, 3D printing, bio-based polymers, and advanced electronics) enhances Arkema's ability to introduce high-value, eco-friendly products that can command premium pricing, supporting long-term revenue growth and gross margin expansion.
See why 32 investors see Arkema as 14% undervalued .
Result: Fair Value of €63.63 (UNDERVALUED)
Still, the narrative can crack if prolonged weak demand in construction and automotive drags on volumes, or if currency swings and higher financing costs continue to squeeze earnings.
Find out about the key risks to this Arkema narrative .
Another View: Arkema Through The Sales Lens
The eye catching story for Arkema is that its share price trades 60.8% below the SWS estimate of future cash flow value of €138.92, yet the P/S ratio tells a much calmer story at 0.5x, almost identical to the estimated fair ratio of 0.5x.
Compared with both peer and wider European chemicals averages at 1x P/S, Arkema changes hands at roughly half the sector multiple, which can signal either a margin of safety if earnings recover as forecast or a warning that the market is still cautious on its mixed profit record. Which side of that trade do you think is closer to reality?
See what the numbers say about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment on Arkema is split, with clear worries on one side and credible upside drivers on the other. Move quickly, review the underlying data for yourself, and weigh both the 2 key rewards and 3 important warning signs in 2 key rewards and 3 important warning signs .
Looking for more Arkema style investment ideas?
If Arkema has your attention, do not stop at one opportunity. Cast a wider net now so you are not watching from the sidelines later.
-
Target potential mispricings by reviewing a curated set of 180 high quality undervalued stocks that combine attractive valuations with solid underlying businesses.
-
Strengthen your downside protection by scanning the 225 resilient stocks with low risk scores that score well on resilience and balance sheet quality.
-
Get ahead of the crowd by hunting through the 620 high quality undiscovered gems before attention and capital rush in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AKE.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
